Navigation Links
AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Date:4/15/2008

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate, with its flagship product candidate, cetrorelix. The study involves approximately 600 patients primarily in the United States and Canada, with additional sites in Europe.

"We are very proud to have reached this important milestone. The Phase 3 program in BPH with cetrorelix is on track and we expect to provide results in the third quarter of 2009 as stated previously," commented Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris.

This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study commenced first patient randomization in April 2007 and completion of patient recruitment was announced today. It is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm sever
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Changes to its Management Team
2. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
3. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
4. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
5. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
6. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... 5 , - Exchange: OTCBB, Immureboost Inc. announced ... Inc., Fountain Healthy Aging Inc. said this approval follows ... Directors and the Shareholders,of the Company., CEO, Dr Tony ... a,new direction and a completely new business plan ", ...
... the first to use rapid, automated DNA sequencing to ... perform microbial ,fingerprinting, ... in the,development of state of the art genomic and informational ... Patent,and Trademark Office (USPTO) recently issued U.S. Patent no. 7,449,808, ...
... 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC ... producer of plant extracts and pharmaceutical raw,materials for ... China, is pleased to announce a Letter of ... Qinba Xintong Medical Ltd. ("Qinba").,Under the proposed terms ...
Cached Biology Technology:Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 2eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections 3Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... lives nestling in the protective tentacles of host anemones, ... travel hundreds of kilometres across the open ocean. Although ... been predicted, this is the first time that the ... been observed. , Dr Steve Simpson, Senior Lecturer in ... Exeter, and colleagues from the Australian Research Council Centre ...
(Date:9/17/2014)... his doctoral student have designed a device based on ... fog and dew., The device could provide water in ... globe., Cheng Luo, professor in the Mechanical & Aerospace ... same College of Engineering department, published "Bioinspired Plate-Based Fog ... Chemical Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... Drugs that target the way cells convert nutrients ... range of conditions including heart attack and stroke. ... a team led by Massachusetts General Hospital (MGH) researchers ... drug, that can shift cellular energy metabolism processes in ...
... proteins found in our intestines can recognize and kill bacteria ... at Emory University School of Medicine have discovered. The ... appear in the journal Nature Medicine . Many ... surfaces of bacteria, but these proteins are different because they ...
... 2010) The wait is over for 16-year-old Francesco "Frank" ... heart in a nine-hour transplant operation at Texas Children,s Heart ... child ever discharged from a pediatric hospital with an implanted ... pediatric patients with VADs remained in the hospital, often in ...
Cached Biology News:Shifting cellular energy metabolism may help treat cardiovascular disease 2Shifting cellular energy metabolism may help treat cardiovascular disease 3Bacteria-killing proteins cover blood type blind spot 2Bacteria-killing proteins cover blood type blind spot 3Texas Children's discharges history-making patient 2
... The StatMatic I provides a convenient and ... culture work. Used with an eight-port disposable ... not possible with multi-channel pipettes. The eight-port ... in volumes of 100, 200, 250, or ...
384 Well PCR Plate Carrier for Thermo-Sealer...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
... are hydrophobic cover slips for in ... genomic arrays on glass slides., ... Hybri-slips do not adsorb probes. , ... to use. , Avoid RNA degradation-Hybri-slips ...
Biology Products: